Combined AbbVie/Allergan Makes Earnings Debut
Executive Summary
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
You may also be interested in...
Deals Or No Deals, J.P. Morgan Sets The Tone For 2022
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
Migraine Market Update: CGRP Inhibitors Slowly Gain Ground
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.
AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis
AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.